TORONTO, June 07, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, hereby informs shareholders that its Annual General Meeting of Shareholders will be held at 10:00 a.m. (EDT) on June 21, 2016 in the Porter Room, at the Courtyard Marriott Downtown Toronto, 475 Yonge Street, Toronto, ON M4Y 1X7.
The Notice of Meeting contains the detailed agenda for the Meeting and the proposed resolutions, and describes the main ways in which shareholders can take part in and vote at the Meeting.
The Notice of Meeting and the Management Information Circular have been mailed to shareholders and have been filed under the Company profile at www.sedar.com as of May 30, 2016, and are available at www.profoundmedical.com.
About Profound Medical Corp.
Profound is a Canadian medical device company that developed a unique and minimally invasive procedure to ablate malignant prostate tissue. The Company’s novel technology combines real-time Magnetic Resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit www.profoundmedical.com.
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts Media: Rebecca von Goetz Senior Marketing & Communications Specialist Profound Medical Corp. email@example.com T: 647.476.1350, Ext. 426 C: 416.917.8650 Investors: Stephen Kilmer Investor Relations firstname.lastname@example.org T: 647.872.4849
Source:Profound Medical Inc.